<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63864">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02040337</url>
  </required_header>
  <id_info>
    <org_study_id>CR-14-021</org_study_id>
    <nct_id>NCT02040337</nct_id>
  </id_info>
  <brief_title>Sequencing T-cells in Type I Diabetes Mellitus</brief_title>
  <official_title>Sequencing T-cell Receptor Repertoire of Auto-Antigen Specific T-cells in Type I Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seton Family of Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seton Clinical Research Pilot Grant Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Prevention Research Institute of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seton Family of Hospitals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate CD8 + T-cell receptor (TCR) repertoire
      differences between patients with type 1 diabetes mellitus and type 2 diabetes or healthy
      controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using a systems biology approach by combining high-throughput sequencing, cytometry, gene
      expression, transcriptome profiling, HLA typing, single cell analysis, and TCR affinity
      assays, the investigators will define a set of immune metrics for the prediction or early
      diagnosis of disease that is superior to the current examination of auto-antibodies, which
      is a fairly late stage in the disease development. This can also be used to guide therapy in
      advanced disease.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Sensitivity and specificity of T cell repertoire analysis to classify Type I Diabetes</measure>
    <time_frame>3 month intervals for 2 years.  Time to assess effectiveness is 1 year.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Endocrinology clinic patients currently receiving treatment for Type II Diabetes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a current or previous diagnosis of Type I Diabetes
             (Autoimmune-related T1DA as confirmed by a positive test for glutamic acid
             decarboxylase (GAD) auto-antibodies.  When available, idiopathic T1DB patients with a
             lack of autoantibodies to GAD will be recruited)

          -  Patients must be ≥ 18 years old and ≤45 years old

          -  Male

          -  Caucasian

        Inclusion criteria: patients T2D as controls

          -  Patients must have a current or previous diagnosis of T2D

          -  Patients must be ≥ 18 years old and ≤45 years old

          -  Male

        Exclusion Criteria:

          -  Non-Caucasian

          -  Female

          -  &lt;18 years old; &gt; 45 years old
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mrinalini Kulkarni-Date, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seton Family of Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Poppy Poth</last_name>
    <phone>512-324-1000</phone>
    <phone_ext>89612</phone_ext>
    <email>pepoth@seton.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas Physicians at Trinity</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Poppy Poth</last_name>
      <phone>512-324-1000</phone>
      <phone_ext>89612</phone_ext>
    </contact>
    <investigator>
      <last_name>Mrinalini Kulkarni-Date, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>February 25, 2014</lastchanged_date>
  <firstreceived_date>January 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
